Deals & Cases (Life Sciences & Healthcare)

04-Sep-2008  |  Life Sciences & Healthcare

Taylor Wessing advises Asterand plc on licence agreement with Allergan Inc

Taylor Wessing's Life Sciences & Healthcare Group has advised new client Asterand plc, a leading global provider of human ... more

03-Sep-2008  |  Life Sciences & Healthcare

Taylor Wessing advises Biota on RSV collaboration and licence agreement

Taylor Wessing's Life Sciences & Healthcare Group has advised new client Biota Holdings Limited, a leading anti-infective ... more

08-Jul-2008  |  Corporate, Life Sciences & Healthcare, Tax, Technology

Taylor Wessing advises NovaThera on £30m merger with MedCell

Taylor Wessing LLP has advised NovaThera on their merger with MedCell, to create a new UK company specialising in musculoskeletal ... more

05-Dec-2007  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises Vivacta on £6 million Series B fundraising

CLIENTVivacta Limited VALUE£6 millionTRANSACTIONSeries B fundraising roundDESCRIPTIONTaylor Wessing in London has acted for ... more

20-Jul-2007  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises Vétoquinol on a €250 million IPO deal

CLIENTVétoquinolVALUE€250 millionTRANSACTIONIPODESCRIPTIONAdvised the underwriter Oddo Corporate Finance on the IPO on the French ... more

13-Apr-2007  |  Corporate, Intellectual Property, Life Sciences & Healthcare, Technology

Taylor Wessing advises Innate Pharma S.A. on its recent in-licensing agreement with Cancer Research Technology Limited

CLIENTInnate Pharma SAVALUENot disclosedTRANSACTIONCollaboration and licensing dealDESCRIPTIONAdvised Innate Pharma S.A. on its ... more

30-Mar-2007  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises Oxford BioMedica on global licensing agreement with sanofi-aventis

CLIENTOxford BioMedicaVALUE€518 million (~US$690 million)TRANSACTIONGlobal licensing agreement DESCRIPTIONTaylor Wessing advised ... more

26-Mar-2007  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises on €9 million subscription and placing for AIM-listed company, Arthro Kinetics plc

CLIENTArtho KineticsVALUE€9 millionTRANSACTIONShares subscription and placingDESCRIPTIONTaylor Wessing advised on €9 million ... more

23-Jan-2007  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises the Debiopharm Group on an exclusive agreement with Cambridge Antibody Technology

CLIENTDebiopharm GroupVALUETransaction ongoingTRANSACTIONLicensing dealDESCRIPTIONAdvised Debiopharm Group on an exclusive ... more

13-Jan-2007  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises UCB on an expanded product license agreement with Jazz Pharmaceuticals

CLIENTUCBVALUETransaction ongoingTRANSACTIONLicensing dealDESCRIPTIONAdvising UCB on an expanded product license agreement for ... more

17-Nov-2006  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises Apax Partners and Merlin Biosciences on a $35 million private equity deal

CLIENTApax Partners and Merlin BiosciencesVALUE$35 millionTRANSACTIONPrivate equity financingDESCRIPTIONAdvised Apax Partners ... more

17-Oct-2006  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises Neurotech France SA in completing a flip transaction into the US

CLIENTNeurotech Pharmaceuticals IncVALUENot disclosedTRANSACTIONRestructuringDESCRIPTIONAdvised Neurotech France SA and its ... more

16-Feb-2006  |  Corporate, Intellectual Property, Life Sciences & Healthcare, Technology

Taylor Wessing advises Bayer Healthcare AG in a divestment of animal health biological vaccines to Intervet

CLIENTBayer Healthcare AGVALUENot disclosedTRANSACTIONM & ADESCRIPTIONAdvised Bayer Healthcare AG on the divestment of the ... more

25-Jul-2005  |  Corporate, Intellectual Property, Life Sciences & Healthcare, Tax

Taylor Wessing advises Xention Discovery Ltd on its £11m venture capital funding

CLIENTXention Discovery LtdDEAL VALUE£11mTRANSACTIONVenture Capital fundingDESCRIPTIONTaylor Wessing's Cambridge office has ... more

28-Jun-2005  |  Corporate, Employment & Pensions, Life Sciences & Healthcare, Technology

Taylor Wessing advises on £4m spinal investment

CLIENTFNI Venture CapitalVALUE£4mTRANSACTIONFundraisingDESCRIPTIONTaylor Wessing has advised FNI Venture Capital on its ... more

27-Jun-2005  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advises on Europe's largest venture capital fund raising this year

CLIENTMPM CapitalVALUE$59.8mTRANSACTIONFundraisingDESCRIPTIONTaylor Wessing has acted for MPM Capital, a global investment firm ... more

07-Jun-2005  |  Corporate, Employment & Pensions, Intellectual Property, Life Sciences & Healthcare, Real Estate, Tax

Taylor Wessing advises Spain's largest cosmetic surgery group on Ultralase Limited acquisition

Taylor Wessing has acted for Corporación Dermoestética SA, the Spanish cosmetic surgery group, on its acquisition of all the ... more

03-Mar-2005  |  Corporate, Intellectual Property, Life Sciences & Healthcare, Tax, Technology

Taylor Wessing's Cambridge office advises on a £20m double act of financing rounds

Taylor Wessing's Cambridge office has advised on a series of technology funding deals for clients ACT Venture Capital and Sphere ... more

26-Jan-2005  |  Corporate, Intellectual Property, Life Sciences & Healthcare, Technology

Taylor Wessing advises First Cambridge Gateway on a £3.2m financing round of DanioLabs

Taylor Wessing advised First Cambridge Gateway Fund on a £3.2m financing round of DanioLabs, the Cambridge-based biotechnology ... more

18-Jan-2005  |  Corporate, Employment & Pensions, Intellectual Property, Life Sciences & Healthcare, Technology

Taylor Wessing advises Advent Venture Partners and Scottish Equity Partners on investment in Rhytec Ltd

Taylor Wessing advises Advent Venture Partners and Scottish Equity Partners on their investment of up to £8 million in Rhytec ... more

18-Jan-2005  |  Corporate, Employment & Pensions, Intellectual Property, Life Sciences & Healthcare, Real Estate

Taylor Wessing advises Paradigm Therapeutics Limited on its merger with Amedis Pharmaceuticals Limted

Taylor Wessing advises Paradigm Therapeutics Ltd on its merger with Amedis Pharmaceuticals Ltd, a medical chemistry and drug ... more

04-Nov-2004  |  Corporate, Employment & Pensions, Intellectual Property, Life Sciences & Healthcare, Private Capital, Real Estate, Tax

Taylor Wessing advise on the sale of DNA Research Innovations Ltd for up to $65 million to Invitrogen Corporation

Taylor Wessing has advised the shareholders of DNA Research Innovations Ltd on its sale to NASDAQ-listed Invitrogen Corporation, ... more

26-Mar-2004  |  Corporate, Life Sciences & Healthcare

Taylor Wessing advised Acolyte Biomedica on £3.7 million funding to launch revolutionary tests to combat superbug

Taylor Wessing advised Acolyte Biomedica Ltd, the UK-based developer of microbiology test systems, on securing £3.7 million in ... more